Brief: Benitec Biopharma Reports Positive Interim Clinical Trial Data For First OPMD Subject Treated With BB-301 In Phase 1b/2a Study

Benitec Biopharma

18/04/2024 13:09

April 18 (Reuters) - Benitec Biopharma Inc  BNTC.O :
    * BENITEC BIOPHARMA REPORTS POSITIVE INTERIM CLINICAL TRIAL
DATA
FOR FIRST OPMD SUBJECT TREATED WITH BB-301 IN PHASE 1B/2A STUDY
    * BENITEC BIOPHARMA: FIRST EFFICACY SIGNALS DEMONSTRATED FOR
GENE
THERAPY UNDER DEVELOPMENT FOR OCULOPHARYNGEAL MUSCULAR DYSTROPHY
(OPMD)
    * BENITEC BIOPHARMA INC: BB-301 FACILITATED IMPROVEMENTS
ACROSS
MULTIPLE MEASURES OF SWALLOWING FUNCTION IN FIRST PHASE 1B/2A
CLINICAL STUDY SUBJECT
    * BENITEC BIOPHARMA INC: BB-301 HAS BEEN GRANTED ORPHAN DRUG
DESIGNATION BY US FDA AND EMA COMMITTEE FOR ORPHAN MEDICINAL
PRODUCTS (COMP)
    * BENITEC BIOPHARMA INC: REGARDING BB-301 SAFETY PROFILE
OBSERVED
TO DATE, NO SERIOUS ADVERSE EVENTS HAVE BEEN OBSERVED FOR TWO
SUBJECTS

Source text for Eikon:  ID:nGNX80tK1H 
Further company coverage:  BNTC.O